Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on Wednesday.

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and Zepbound.

Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These medications, from Novo Nordisk and Eli Lilly, typically cost much more. The $200 co-pays contribute to deductibles,